4.5 Article

A New Prediction Model for Evaluating Treatment-Resistant Depression

期刊

JOURNAL OF CLINICAL PSYCHIATRY
卷 78, 期 2, 页码 215-+

出版社

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.15m10381

关键词

-

向作者/读者索取更多资源

Objective: Despite a broad arsenal of antidepressants, about a third of patients suffering from major depressive disorder (MDD) do not respond sufficiently to adequate treatment. Using the data pool of the Group for the Study of Resistant Depression and machine learning, we intended to draw new insights featuring 48 clinical, sociodemographic, and psychosocial predictors for treatment outcome. Method: Patients were enrolled starting from January 2000 and diagnosed according to DSM-IV. Treatment-resistant depression (TRD) was defined by a 17-item Hamilton Depression Rating Scale (HDRS) score >= 17 after at least 2 antidepressant trials of adequate dosage and length. Remission was defined by an HDRS score < 8. Stepwise predictor reduction using randomForest was performed to find the optimal number for classification of treatment outcome. After importance values were generated, prediction for remission and resistance was performed in a training sample of 400 patients. For prediction, we used a set of 80 patients not featured in the training sample and computed receiver operating characteristics. Results: The most useful predictors for treatment outcome were the timespan between first and last depressive episode, age at first antidepressant treatment, response to first antidepressant treatment, severity, suicidality, melancholia, number of lifetime depressive episodes, patients' admittance type, education, occupation, and comorbid diabetes, panic, and thyroid disorder. While single predictors could not reach a prediction accuracy much different from random guessing, by combining all predictors, we could detect resistance with an accuracy of 0.737 and remission with an accuracy of 0.850. Consequently, 65.5% of predictions for TRD and 77.7% for remission can be expected to be accurate. Conclusions: Using machine learning algorithms, we could demonstrate success rates of 0.737 for predicting TRD and 0.850 for predicting remission, surpassing predictive capabilities of clinicians. Our results strengthen data mining and suggest the benefit of focus on interaction-based statistics. Considering that all predictors can easily be obtained in a clinical setting, we hope that our model can be tested by other research groups.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Psychology, Clinical

Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank

Chiara Fabbri, Julian Mutz, Cathryn M. Lewis, Alessandro Serretti

Summary: This study was the first to comprehensively evaluate the predictors of wellbeing in relation to the history of MDD. The identified variables are important to identify individuals at risk and promote wellbeing.

PSYCHOLOGICAL MEDICINE (2023)

Article Psychiatry

Cariprazine for treating psychosis: an updated meta-analysis

Marcelo B. Generoso, Ivan Taiar, Quirino Cordeiro, Pedro Shiozawa, Siegfried Kasper

Summary: Early treatment of psychotic illness is important for better outcomes, and cariprazine, a promising antipsychotic drug, may be beneficial in treating psychosis regardless of the diagnosis of schizophrenia or bipolar disorder.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Editorial Material Neurosciences

Investigation of Psychoactive Medications: Challenges and a Practical and Scalable New Path

Dekel Taliaz, Alessandro Serretti

Summary: The validity of clinical trials in psychiatry has been under discussion in the past two decades. The commonly used method of randomized controlled trials (RCTs) faces challenges when applied in the psychiatric field due to strict participant criteria and inconsistency in endpoint parameters. This has led to problematic clinical practice in psychiatry.

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2023)

Article Psychiatry

Factors associated with sick leave duration in patients suffering from major depressive disorder initiating antidepressant treatment: a real-world evidence study in Germany and Spain

Miquel Roca, Annalisa Bonelli, Agnese Cattaneo, Alessandro Comandini, Giorgio Di Dato, Franca Heiman, Valeria Pegoraro, Siegfried Kasper, Hans-Peter Volz, Diego Palao

Summary: This study explores the impact of pharmacological approaches in treating MDD patients and identifies factors associated with longer sick leave duration. Combination/switch/add-on treatments are associated with a higher risk of longer sick leave periods, while timely and careful selection of antidepressant treatment approach may help reduce sick leave.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Review Psychiatry

Subthreshold depression - concept, operationalisation and epidemiological data. A scoping review

Hans-Peter Volz, Johanna Stirnweiss, Siegfried Kasper, Hans-Juergen Moeller, Erich Seifritz

Summary: This paper reviews the research on subthreshold depression (SD) based on a scoping review. The results show that the operationalisation criteria used are highly heterogeneous, leading to inconsistent epidemiological data. The impact of SD on quality of life and related parameters is similar to that of major depression, and therapeutic approaches can be helpful in both preventing and treating SD.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Article Pharmacology & Pharmacy

Patterns of antipsychotic prescription and accelerometer-based physical activity levels in people with schizophrenia spectrum disorders: a multicenter, prospective study

Vincenzo Oliva, Giuseppe Fanelli, Manuel Zamparini, Cristina Zarbo, Matteo Rocchetti, Letizia Casiraghi, Fabrizio Starace, Alessandra Martinelli, Alessandro Serretti, Giovanni de Girolamo, DiAPASon Consortium

Summary: Antipsychotic polypharmacy (APP) is commonly used in patients with schizophrenia spectrum disorders (SSDs) despite recommendations against it. This study found high rates of APP and lower levels of physical activity in both residential and outpatient patients. However, patients on APP showed trends of reduced sedentariness and higher levels of light physical activity compared to those on monopharmacy.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Review Psychiatry

Mental fatigue in individuals with psychiatric disorders: a scoping review

Kristina Mozuraityte, Agne Stanyte, Naomi A. Fineberg, Alessandro Serretti, Julija Gecaite-Stonciene, Julius Burkauskas

Summary: This study conducted a scoping review of published literature to examine the relationship between mental fatigue and various psychiatric disorders. The findings suggest that mental fatigue is studied in mood disorders, anxiety disorders, obsessive-compulsive disorder, and obsessive-compulsive personality disorder. Cognitive factors such as unhelpful beliefs about sleep and symptom-focussed rumination, as well as personality risk factors, were found to be relevant in predicting mental fatigue symptoms. Further investigation is needed to explore mental fatigue in adult psychiatric samples.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Article Psychiatry

Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting

Fabio Panariello, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Alessandro Serretti, Chiara Fabbri

Summary: This study aimed to identify factors associated with side effects of psychotropic drugs in a real-world setting enriched with treatment-resistant depression (TRD) patients. Results showed that the severity of depressive symptoms was associated with total, psychic, and neurological side effects, while autonomic side effects were higher in patients with somatic comorbidities and lower in patients receiving trazodone. Multivariate analyses revealed that depressive symptom severity was associated with psychic and total side effects, generalized anxiety disorder (GAD) with neurological side effects, and somatic comorbidities remained associated with autonomic side effects. Trazodone was associated with lower side effects and with augmentation treatments. Augmentation therapies showed opposite effects depending on response status, i.e. increased or decreased the risk of side effects in responders and non-responders/resistant patients, respectively.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2023)

Letter Clinical Neurology

Silexan for treatment of anxiety and depression in the context of COVID-19

Lucie Bartova, Markus Dold, Gernot Fugger, Ana Weidenauer, Dan Rujescu, Siegfried Kasper

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2023)

Editorial Material Pharmacology & Pharmacy

In search of clinical targets for suicide prevention in major depressive disorder

Paolo Olgiati, Alessandro Serretti

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Article Clinical Neurology

Effects of bilateral sequential theta-burst stimulation on functional connectivity in treatment-resistant depression: First results

Peter Stohrmann, Godber Mathis Godbersen, Murray Bruce Reed, Jakob Unterholzner, Manfred Klobl, Pia Baldinger-Melich, Thomas Vanicek, Andreas Hahn, Rupert Lanzenberger, Siegfried Kasper, Georg S. Kranz

Summary: This longitudinal study investigated the effect of bilateral sequential theta-burst stimulation (TBS) on functional connectivity (FC) in treatment-resistant depression (TRD). Results showed that both active and sham stimulation groups exhibited reductions in depression scores, with no significant difference between the two groups. Baseline FC between the left dorsolateral prefrontal cortex (DLPFC) and the subgenual cingulate cortex (sgACC) was correlated with changes in depression severity. TBS significantly reduced FC between the left stimulation target and bilateral anterior insula, highlighting the effect on the salience network.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Editorial Material Psychiatry

Cheers and a thank-you note from the founding chief-editor

Siegfried Kasper

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Article Endocrinology & Metabolism

The influence of sex steroid treatment on insular connectivity in gender dysphoria

Murray B. Reed, Patricia A. Handschuh, Manfred Kloebl, Melisande E. Konadu, Ulrike Kaufmann, Andreas Hahn, Georg S. Kranz, Marie Spies, Rupert Lanzenberger

Summary: This study investigated the effects of sex steroids on insular connectivity. The findings showed increased connectivity in transgender women receiving gender-affirming hormone therapy. Additionally, gender-affirming hormone therapy led to changes in alexithymia in transgender women.

PSYCHONEUROENDOCRINOLOGY (2023)

Article Psychiatry

Age as a moderating factor of treatment resistance in depression

Alexander Kautzky, Lucie Bartova, Gernot Fugger, Markus Dold, Daniel Souery, Stuart Montgomery, Joseph Zohar, Julien Mendlewicz, Chiara Fabbri, Alessandro Serretti, Dan Rujescu, Siegfried Kasper

Summary: This study investigates the differences in presentation and treatment outcomes of treatment-resistant depression (TRD) among different age groups. It finds that age has an impact on depressive symptoms and treatment outcomes. In TRD patients, symptom load and hospitalization time increase with age, while treatment responders do not show this trend. Older patients are more likely to have symptoms such as inner tension, reduced appetite, concentration difficulties, and lassitude.

EUROPEAN PSYCHIATRY (2023)

暂无数据